CA2403909A1 - Compositions and methods for the therapy and diagnosis of prostate cancer - Google Patents

Compositions and methods for the therapy and diagnosis of prostate cancer Download PDF

Info

Publication number
CA2403909A1
CA2403909A1 CA002403909A CA2403909A CA2403909A1 CA 2403909 A1 CA2403909 A1 CA 2403909A1 CA 002403909 A CA002403909 A CA 002403909A CA 2403909 A CA2403909 A CA 2403909A CA 2403909 A1 CA2403909 A1 CA 2403909A1
Authority
CA
Canada
Prior art keywords
seq
sequence
cdna sequence
polypeptide
sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002403909A
Other languages
English (en)
French (fr)
Inventor
Jiangchun Xu
Davin C. Dillon
Jennifer L. Mitcham
Susan L. Harlocker
Yuqiu Jiang
Michael D. Kalos
Gary Richard Fanger
Marc W. Retter
John A. Stolk
Craig H. Day
Thomas S. Vedvick
Darrick Carter
Samuel X. Li
Aijun Wang
Yasir A. W. Skeiky
William T. Hepler
Robert A. Henderson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corixa Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/570,737 external-priority patent/US7202342B1/en
Priority claimed from US09/593,793 external-priority patent/US7517952B1/en
Priority claimed from US09/636,215 external-priority patent/US6620922B1/en
Priority claimed from US09/651,236 external-priority patent/US6818751B1/en
Priority claimed from US09/657,279 external-priority patent/US6894146B1/en
Priority claimed from US09/679,426 external-priority patent/US6759515B1/en
Priority claimed from US09/685,166 external-priority patent/US6630305B1/en
Application filed by Individual filed Critical Individual
Publication of CA2403909A1 publication Critical patent/CA2403909A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA002403909A 2000-03-27 2001-03-27 Compositions and methods for the therapy and diagnosis of prostate cancer Abandoned CA2403909A1 (en)

Applications Claiming Priority (23)

Application Number Priority Date Filing Date Title
US53685700A 2000-03-27 2000-03-27
US09/536,857 2000-03-27
US56810000A 2000-05-09 2000-05-09
US09/568,100 2000-05-09
US09/570,737 2000-05-12
US09/570,737 US7202342B1 (en) 1999-11-12 2000-05-12 Compositions and methods for the therapy and diagnosis of prostate cancer
US09/593,793 2000-06-13
US09/593,793 US7517952B1 (en) 1997-02-25 2000-06-13 Compositions and methods for the therapy and diagnosis of prostate cancer
US60578300A 2000-06-27 2000-06-27
US09/605,783 2000-06-27
US09/636,215 US6620922B1 (en) 1997-02-25 2000-08-09 Compositions and methods for the therapy and diagnosis of prostate cancer
US09/636,215 2000-08-10
US09/651,236 US6818751B1 (en) 1997-08-01 2000-08-29 Compositions and methods for the therapy and diagnosis of prostate cancer
US09/651,236 2000-08-29
US09/657,279 US6894146B1 (en) 1997-02-25 2000-09-06 Compositions and methods for the therapy and diagnosis of prostate cancer
US09/657,279 2000-09-06
US09/679,426 US6759515B1 (en) 1997-02-25 2000-10-02 Compositions and methods for the therapy and diagnosis of prostate cancer
US09/679,426 2000-10-02
US09/685,166 US6630305B1 (en) 1999-11-12 2000-10-10 Compositions and methods for the therapy and diagnosis of prostate cancer
US09/685,166 2000-10-10
US70972900A 2000-11-09 2000-11-09
US09/709,729 2000-11-09
PCT/US2001/009919 WO2001073032A2 (en) 2000-03-27 2001-03-27 Compositions and methods for the therapy and diagnosis of prostate cancer

Publications (1)

Publication Number Publication Date
CA2403909A1 true CA2403909A1 (en) 2001-10-04

Family

ID=27582800

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002403909A Abandoned CA2403909A1 (en) 2000-03-27 2001-03-27 Compositions and methods for the therapy and diagnosis of prostate cancer

Country Status (5)

Country Link
EP (1) EP1311673A2 (enExample)
JP (1) JP2004504808A (enExample)
AU (1) AU2001249549A1 (enExample)
CA (1) CA2403909A1 (enExample)
WO (1) WO2001073032A2 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030185830A1 (en) 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7517952B1 (en) 1997-02-25 2009-04-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
AU7019498A (en) 1997-04-10 1998-10-30 Diagnocure Inc. Pca3, pca3 genes, and methods of use
US20030149531A1 (en) 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
AU757698C (en) 1998-06-01 2004-04-08 Agensys, Inc. Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
US7037667B1 (en) 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US6943235B1 (en) 1999-04-12 2005-09-13 Agensys, Inc. Transmembrane protein expressed in prostate cancer
ES2260059T3 (es) 1999-09-29 2006-11-01 Diagnocure Inc. Rna mensajero del pca3 en tejidos benignos y malignos de prostata.
US6790631B1 (en) 1999-10-05 2004-09-14 Agensys, Inc. G protein-coupled receptor up-regulated in prostate cancer and uses thereof
US7208280B2 (en) 1999-10-05 2007-04-24 Agensys, Inc. Nucleic acid and corresponding protein entitled 101P3A41 useful in treatment and detection of cancer
US7361338B2 (en) 1999-10-05 2008-04-22 Agensys, Inc. Methods to inhibit growth of prostate cancer cells
DK1517913T3 (da) * 1999-10-07 2007-06-18 Corixa Corp En Mycobacterium tuberculosis-kodende sekvens til ekspression af heterologe proteiner
DE60139963D1 (de) 2000-06-20 2009-10-29 Corixa Corp Fusionsproteine aus mycobakterium tuberculosis
EP2339035A1 (en) 2000-12-07 2011-06-29 Novartis Vaccines and Diagnostics, Inc. Endogenous retroviruses up-regulated in prostate cancer
EP2280030A3 (en) 2001-04-10 2011-06-15 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
CA2446788A1 (en) * 2001-05-09 2002-11-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
CA2447564A1 (en) * 2001-05-15 2002-11-21 Agensys, Inc. Nucleic acids and corresponding proteins entitled 101p3a11 or phor-1 useful in treatment and detection of cancer
US6897024B2 (en) 2001-05-31 2005-05-24 Stichting Katholieke Universiteit More Particularly The University Medical Centre Nijmegen Nucleic acid molecules comprising the promoter for PCA3, and uses thereof
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US7332290B2 (en) 2001-08-02 2008-02-19 The Regents Of The University Of Michigan Dectection of AMACR cancer markers in urine
US7700293B2 (en) 2001-08-02 2010-04-20 The Regents Of The University Of Michigan Expression profile of prostate cancer
AU2002336446B2 (en) 2001-09-06 2008-03-06 Agensys, Inc. Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
EP1474516B1 (en) 2002-01-25 2013-03-27 The Regents of The University of California Methods of modulating cold sensory perception
DK1511768T3 (da) * 2002-06-11 2007-08-20 Glaxosmithkline Biolog Sa Immunogene sammensætninger
AU2003243151A1 (en) 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
AU2004209578A1 (en) 2003-02-07 2004-08-19 Diagnocure Inc. Method to detect prostate cancer in a sample
NZ550816A (en) 2004-04-22 2009-12-24 Agensys Inc Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
CA2491067A1 (en) 2004-12-24 2006-06-24 Stichting Katholieke Universiteit Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer
JP4969444B2 (ja) * 2005-06-14 2012-07-04 ディナベック株式会社 抗体の作製方法
ES2494843T3 (es) 2005-09-19 2014-09-16 Janssen Diagnostics, Llc Métodos y materiales para identificar el origen de un carcinoma de origen primario desconocido
US7622573B2 (en) * 2006-01-17 2009-11-24 Biolex, Inc. Expression control elements from the lemnaceae family
WO2007100568A2 (en) * 2006-02-24 2007-09-07 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services T cell receptors and related materials and methods of use
US7820174B2 (en) 2006-02-24 2010-10-26 The United States Of America As Represented By The Department Of Health And Human Services T cell receptors and related materials and methods of use
AU2007308792B2 (en) 2006-10-27 2013-01-24 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
GB201513921D0 (en) * 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
SG11201909218RA (en) 2017-04-03 2019-11-28 Hoffmann La Roche Antibodies binding to steap-1
WO2024052922A1 (en) * 2022-09-11 2024-03-14 Yeda Research And Development Co. Ltd. Anti-klk4 antibodies and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100340610B1 (ko) * 1997-02-19 2002-06-12 야마모토 카즈모토 분해성 피복 필름으로 피복된 입상 비료 및 이의 제조 방법
US20030185830A1 (en) * 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
ES2248891T3 (es) * 1997-02-25 2006-03-16 Corixa Corporation Compuestos para inmunodiagnostico de cancer de prostata y metodos para su uso.
JP2002520054A (ja) * 1998-07-14 2002-07-09 コリクサ コーポレイション 前立腺癌の治療及び診断のための組成物及び方法
AU7994200A (en) * 1999-10-04 2001-05-10 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
EP1230364A2 (en) * 1999-11-12 2002-08-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
WO2001051633A2 (en) * 2000-01-14 2001-07-19 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
CA2446788A1 (en) * 2001-05-09 2002-11-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer

Also Published As

Publication number Publication date
JP2004504808A (ja) 2004-02-19
WO2001073032A2 (en) 2001-10-04
WO2001073032A3 (en) 2003-03-13
AU2001249549A1 (en) 2001-10-08
EP1311673A2 (en) 2003-05-21

Similar Documents

Publication Publication Date Title
US6800746B2 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
US7939646B2 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
US7033827B2 (en) Prostate-specific polynucleotide compositions
EP1988097A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
CA2397741A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
EP1311673A2 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
US6943236B2 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
US7074898B2 (en) Compositions and methods for therapy and diagnosis of prostate cancer
JP2004537252A (ja) 前立腺癌の治療及び診断のための組成物及び方法
US20020192763A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
US6620922B1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
US6630305B1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
US6759515B1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
US6818751B1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
US20020193296A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
US20020081680A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
US7048931B1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
US6894146B1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
US20020051977A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
US7517952B1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
US20060269532A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
JP2008271978A (ja) 前立腺癌の治療及び診断のための組成物及び方法

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued